Experienced in Embryonal Tumor with Multilayered Rosettes
Experienced in Embryonal Tumor with Multilayered Rosettes
Msu Health Care Inc
1200 E Michigan Ave, Suite 145, 
Lansing, MI 

Overview

Renuka Gera is a Pediatric Hematologist Oncology provider in Lansing, Michigan. Dr. Gera is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Blood Clots, and Acute Lymphoblastic Leukemia (ALL).

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 24 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 4 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in MI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MSU HEALTH CARE INC
1200 E Michigan Ave, Suite 145, Lansing, MI 48912

Additional Areas of Focus

Dr. Gera has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


24 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
View 23 Less Clinical Trials
Similar Doctors
Elite in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Elite in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (51.4 miles away)
Languages Spoken:
English

Gregory Yanik is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Yanik is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr, Suite 0331, 
Ann Arbor, MI 
 (51.2 miles away)
Languages Spoken:
English

Rajen Mody is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Mody is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Infantile Neutropenia, Glioma, and Bone Marrow Aspiration.

Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Pediatric Hematology Oncology
1500 E Medical Center Dr, 
Ann Arbor, MI 
 (51.6 miles away)
Languages Spoken:
English

Carl Koschmann is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Koschmann is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Glioma, Brain Stem Cancer, and Embryonal Tumor with Multilayered Rosettes.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gera's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile